BACKGROUND: Coronavirus disease-2019 (COVID-19) is associated with
hypercoagulability and increased thrombotic risk in critically ill patients. To our knowledge …

Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …

Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID‐19) are
related to the higher mortality rate. Because of limited data on the antiplatelet effect, we …

There is growing evidence that thrombotic and inflammatory pathways contribute to the
severity of COVID-19. Common medications such as aspirin, that mitigate these pathways …

Importance Prior observational studies suggest that aspirin use may be associated with
reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in …

Background Repurposing the use of aspirin to treat hospitalized patients with COVID-19 is a
sensible approach. However, several previous studies showed conflicting results. This meta …

Rationales and uncertainties for aspirin use in COVID-19: a narrative review - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Background This study aimed to investigate whether the active prescription of low-dose
aspirin during or prior to hospitalization affects mortality in patients with coronavirus disease …

Background Thromboembolic disease is common in coronavirus disease-2019 (COVID-19).
There is limited evidence on the association of in-hospital anticoagulation (AC) with …

Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …